Entrada Therapeutics Q2 EPS $(0.78) Down From $(0.74) YoY; $377M In Cash, Cash Equivalents And Marketable Securities, With Cash Runway Through 2025
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics reported Q2 losses of $(0.78) per share, a 5.41% decrease YoY. The company has $377M in cash, cash equivalents, and marketable securities, providing a cash runway through 2025.
August 08, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Entrada Therapeutics reported a YoY decrease in Q2 losses. Despite this, the company has a strong cash position, which could provide stability in the short term.
While the YoY decrease in Q2 losses is a negative sign, the company's strong cash position, which is expected to last through 2025, could provide some stability to the stock in the short term. However, the overall impact is likely to be neutral as the market weighs these factors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100